Dr. Taylor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3901 Rainbow Blvd
Dept of Urology, KUMC
Kansas City, KS 66160Phone+1 913-588-6146- Is this information wrong?
Summary
- Dr. John Taylor is an urologist in Kansas City, KS and is affiliated with multiple hospitals in the area, including The University of Kansas Hospital and Truman Medical Center-Hospital Hill. He received his medical degree from Columbia University College of Physicians & Surgeons and has been in practice 23 years. He specializes in surgical oncology.
Clinical Expertise
- Urothelial carcinoma, Bladder cancer
Education & Training
- University of ConnecticutMS, Clinical & Translational Research, 2010
- University of ConnecticutM.S., Clinical and Translational Research, 2010
- New York Presbyterian Hospital (Cornell Campus)Residency, Urology, 1996 - 2000
- New York Presbyterian Hospital (Cornell Campus)Residency, Surgery, 1994 - 1996
- Columbia University Vagelos College of Physicians and SurgeonsClass of 1994
- Lafayette CollegeA.B., Biology, 1990
Certifications & Licensure
- NY State Medical License 1997 - Present
- MO State Medical License 2017 - 2024
- KS State Medical License 2016 - 2023
- CT State Medical License 2003 - 2016
- American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2013
- Best Doctors in America Castle Connelly, 2011-2016
- Best Doctors for the Greater Hartford Area Hartford Magazine, 2009
- Join now to see all
Clinical Trials
- Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors Start of enrollment: 2020 Nov 25
- Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors Start of enrollment: 2019 May 19
Publications & Presentations
PubMed
- 2 citationsFosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex.Scott Weir, Prasad Dandawate, David Standing, Sangita Bhattacharyya, Prabhu Ramamoorthy, Parthasarathy Rangarajan, Robyn Wood, Amanda E. Brinker, Benjamin L. Woolbrigh...> ;Cell Death & Disease. 2021 May 31
- 20 citationsBest Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours.Hugh Mostafid, Ashish M. Kamat, Siamak Daneshmand, Joan Palou, John A. Taylor, James M. McKiernan, James W.F. Catto, Marko Babjuk, Mark S. Soloway> ;European Urology Oncology. 2021 Feb 1
- 15 citationsThe Development of Hsp90β-Selective Inhibitors to Overcome Detriments Associated with pan-Hsp90 Inhibition.Sanket J. Mishra, Weiya Liu, Kristin Beebe, Monimoy Banerjee, Caitlin N. Kent, Vitumbiko Munthali, John Koren, John A. Taylor, Leonard M. Neckers, Jeffrey M. Holzbeier...> ;Journal of Medicinal Chemistry. 2021 Jan 11
- Join now to see all
Journal Articles
- Innovation in bladder cancer immunotherapyGrossman HB, Lamm DL, Kamat AM, Keefe S, Taylor JA, Ingersoll MA, J Immunother, 1/1/2016
- Urethral duct invasion in female urethral melanomaUrban J, Bayart CB, Taylor JA, Hegde U, Forouhar F, Dadras SS, Human Pathology: Case Reports, 1/1/2016
- Collaborating to Move Research Forward: Proceedings from the 10th Annual Bladder Cancer Think TankKamat AM, Agarwal P, Bivalacqua T, Chisolm S, Daneshmand S, Doroshow JH, Efstathiou JA, Galsky M, Iyer G, Kassouf W, Shah J, Taylor JA, Williams SB, Quale DZ, Rosenber..., Bladder Cancer, 1/1/2016
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Potential role of G1P3 in development of chemoresistance in high grade bladder cancerAlam SM, Choudhary D, Dancik G, Pilbeam CC, Taylor JA, J Urol, 1/1/2016
- Osteopontin – a potential marker for chemotherapy resistance in bladder cancerGibson N, Choudhary D, Pilbeam CC, Taylor JA, J Urol, 1/1/2016
- Potential role of G1P3 in development of chemoresistance in high grade bladder cancerTaylor JA, American Urological Association Annual Meeting, Bladder Cancer Basic Science Session, San Diego, CA, 1/1/2016
- Join now to see all
Lectures
- Management of high grade non-muslce invasive bladder cancerSan Diego, CA - 1/1/2016
- Concept to Reality the Albert InstituteAthens, Greece - 1/1/2015
- Immunotherapy and Bladder Cancer, What’s On the HorizonMinneapolis, MN - 1/1/2015
- Join now to see all
Other
- GRS Teaching SlidesTaylor JA, American Geriatrics Society
http://www.geriatricscareonline.org
NY - 1/1/2013
Press Mentions
- 2019 Urology Care Foundation Research Scholar Awardees AnnouncedMarch 21st, 2019
Hospital Affiliations
- The University of Kansas HospitalKansas City, Kansas
- Truman Medical Center-Hospital HillKansas City, Missouri
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: